459 results on '"Rech, Jürgen"'
Search Results
2. Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome
3. Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis
4. Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry
5. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
6. Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline
7. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial
8. DGRh-S2e-Leitlinie: Diagnostik und Therapie des adulten Still-Syndroms (AOSD)
9. Leitlinienreport zur DGRh-S2e-Leitlinie Diagnostik und Therapie des adulten Still-Syndroms (AOSD)
10. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
11. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial
12. Erratum to: Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline
13. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
14. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
15. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
16. Patient Experiences and Challenges in the Management of Autoinflammatory Diseases—Data from the International FMF & AID Global Association Survey
17. Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
18. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis
19. Autoinflammation leading to autoimmunity in adult-onset Still’s disease: more than simple coincidence?
20. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
21. Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases
22. Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
23. Methods for segmentation of rheumatoid arthritis bone erosions in high-resolution peripheral quantitative computed tomography (HR-pQCT)
24. Towards a pro-resolving concept in systemic lupus erythematosus
25. Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry
26. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients—A longitudinal analysis
27. Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial
28. Secukinumab leads to shifts from stage-based towards response-based disease clusters—comparative data from very early and established psoriatic arthritis
29. Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis
30. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations
31. IgA subclasses have different effector functions associated with distinct glycosylation profiles
32. Organisation einer Studienambulanz und prüfstellenspezifische Formalitäten
33. Physical Function of RA patients Tapering Treatment—A Post Hoc Analysis of the Randomized Controlled RETRO Trial
34. High prevalence of tenosynovial inflammation before onset of rheumatoid arthritis and its link to progression to RA—A combined MRI/CT study
35. Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia
36. Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway
37. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs
38. VEXAS syndrome mimicking lupus-like disease
39. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
40. Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline
41. DGRh-S2e-Leitlinie
42. Brain oedema due to disseminated intravascular coagulation in a patient with adult-onset Still’s disease–associated hemophagocytic lymphohistiocytosis—a case report
43. Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis
44. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
45. Erste Analysen zu einer durch Patienten mit autoinflammatorischen Erkrankungen organisierten internationalen Befragung – FMF&AID
46. Die 'ARIAA-Studie' – Abatacept verzögert den Übergang in eine RA bei at-risk-Patienten – klinische Ergebnisse zu Monat 18 der internationalen, randomisiert, placebo kontrollierten Studie
47. Langzeitwirksamkeit und Sicherheit von Canakinumab bei Patienten mit HIDS (Hyper-IgD-Syndrom) – Interimsanalyse des RELIANCE-Registers
48. VERhO – patientenindividuelles Tapering von DMARDs bei Patienten mit rheumatoider Arthritis in der Versorgungspraxis
49. Impfsicherheit unter Canakinumab bei Patienten mit autoinflammatorischen periodischen Syndromen – Interimsanalyse des RELIANCE-Registers
50. Add-on or withdrawal of methotrexate do not impact efficacy of IL12/23 inhibition in active PsA: Data from the multicenter investigator-initiated randomized placebo-controlled MUST trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.